49 results about "IV Chemotherapy" patented technology

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The present disclosure relates to 1-(2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)acetyl)-4- hydroxypyrrolidine-2-carboxamide derivatives and structurally related compounds of formula (I) as VHL inhibitors for the treatment of e.g. anemia (e.g. chronic anemia or anemia associated with chronic kidney disease, dialysis or cancer chemotherapy), ischemia, stroke or injury to the cardiovascular system during ischemia, or for enhancing wound healing, reducing scarring or enhancing angiogenesis or arteriogenesis.

This invention provides a chemotherapy catheter for spinal tuberculosis, comprising a catheter with a drug channel, a flexible tube at the front end of the catheter with multiple through holes communicating with the drug channel, and a built-in one-way structure. The one-way structure includes an elastic rubber sheet at one end fixed to the inner wall of the drug channel; multiple elastic rubber sheets are stacked together in a conical shape; and a connector is connected to the rear end of the catheter, with a drug injection end for injecting medication. This invention, by inserting the catheter into the patient's body, injects medication through the drug injection end, which then passes through the drug channel and the one-way structure to prevent backflow, and finally flows out through the multiple through holes, thereby widely dispersing the medication and improving drug utilization.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to the application of a formula for nourishing vital energy and strengthening the body in reducing the toxicity of adjuvant chemotherapy after radical resection of non-small cell lung cancer. This invention discloses a formula for nourishing vital energy and strengthening the body, characterized in that it is composed of the following components by weight: 15-30 parts raw Astragalus membranaceus, 9-21 parts prepared Rehmannia glutinosa, 15-30 parts stir-fried Dioscorea opposita, 9-15 parts Atractylodes macrocephala, 9-15 parts Poria cocos, 15-30 parts raw Coix lacryma-jobi, 9-15 parts Ophiopogon japonicus, 9-15 parts Asparagus cochinchinensis, 15-30 parts Adenophora stricta, 9-15 parts Ligustrum lucidum, 9-15 parts Eclipta prostrata, 9-15 parts stir-fried germinated barley, 9-15 parts stir-fried malt, and 3-6 parts prepared Glycyrrhiza uralensis. This invention can restore vital energy, reverse postoperative weakness, build a foundation for chemotherapy tolerance to reduce toxic side effects, improve chemotherapy tolerance, reduce the risk of interruption to ensure efficacy, improve quality of life during chemotherapy, and help prolong postoperative survival.

The application provides application of a selective splicing factor SF3A2 as a biomarker in preparation of a reagent for breast cancer diagnosis, treatment, prognosis evaluation and chemotherapy sensitivity evaluation. The application provides application of a detection reagent for expression level of a selective splicing factor SF3A2 gene or protein in preparation of a kit for breast cancer diagnosis, prognosis evaluation and chemotherapy sensitivity evaluation. Further, the application provides application of an expression inhibitor for a selective splicing factor SF3A2 gene or protein in preparation of a kit for breast cancer treatment and chemotherapy sensitivity improvement.

This invention discloses an intraperitoneal infusion device, comprising: a hyperthermic chemotherapy perfusion machine; an infusion assembly including a connecting catheter connected to the hyperthermic chemotherapy perfusion machine, the connecting catheter being detachably connected to a drainage catheter, the drainage catheter being inserted into the abdominal cavity via a guidewire; a catheter positioning assembly including an annular mounting band tightened on the abdominal cavity, the annular mounting band having a central clearance hole on its side near the abdominal cavity, the inner side of the central clearance hole being fitted with an inner fitting for positioning the drainage catheter; and a catheter adjustment assembly for adjusting the offset direction of the drainage catheter, including an adaptive adjustment element mounted on the top surface of the annular mounting band, the top of the adaptive adjustment element extending to the drainage catheter, and the lower end of the adaptive adjustment element having a precision pressure measuring element that fits against the abdomen. This invention can adjust the state of the infusion tube in real time when the patient turns over, thereby ensuring stability during the infusion process.

This invention discloses a novel class of monoacylglycerol lipase (MAGL) small molecule inhibitors, as well as their pharmaceutically acceptable compositions, methods of preparation, and uses. The MAGL small molecule inhibitors are represented by formula (I), having the specific substituents and definitions described herein. The disclosed MAGL small molecule inhibitors exhibit excellent MAGL enzyme inhibitory activity. This invention includes these compounds or their pharmaceutically acceptable compositions for the treatment and / or prevention of MAGL-related conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colorectal cancer lesions, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or pain-related spasticity.

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.

This invention discloses the application of P4HB as a target in the preparation of therapeutic drugs for metastatic pleural and peritoneal effusions in multiple cancer types. Through combined single-cell transcriptomics and proteomics analysis, this invention revealed that P4HB is significantly overexpressed in metastatic pleural and peritoneal effusion lesions. Multiplex immunofluorescence and immunohistochemistry were used to perform in situ tissue validation in clinical samples of pleural and peritoneal effusions from breast cancer, lung cancer, gastric cancer, colorectal cancer, and ovarian cancer, clarifying the differential expression characteristics of P4HB in metastatic tumor cells and its correlation with poor prognosis. In patient-derived organoid models, targeting and inhibiting P4HB activity with small molecule inhibitors significantly reduced organoid growth capacity and survival rate, and showed a synergistic sensitizing effect on chemotherapeutic drugs. This invention reveals the use of P4HB as a therapeutic target for metastatic pleural and peritoneal effusions in multiple cancer types, providing a new target and direction for drug development in precision medicine.

This invention discloses a TCM syndrome differentiation model for breast cancer chemotherapy, including four syndrome types: liver stagnation and yin deficiency, qi and yin deficiency, spleen deficiency and blood deficiency, and qi stagnation and blood stasis, as well as discrimination thresholds; the discrimination threshold for all four syndrome types is 22.5. This invention also relates to a system and method for constructing a TCM syndrome differentiation model for breast cancer chemotherapy. This invention combines TCM with statistics and big data to construct a TCM syndrome differentiation model for breast cancer chemotherapy and establishes a method for constructing the model. The model constructed by this invention standardizes and normalizes the application of TCM in breast cancer chemotherapy, providing a new model for the research, application, and promotion of TCM syndrome differentiation.

The application discloses application of a Blautia in preparation of a drug for enhancing sensitivity of colorectal cancer to oxaliplatin, B-CM can significantly enhance OXa cytotoxicity on drug-resistant colorectal cancer cells, inhibit proliferation, clone formation, migration and invasion ability. Combination therapy can synergistically induce apoptosis, although the expression of MDR1 in drug-resistant cells is up-regulated, but the combination of B-CM and OXa can significantly reduce the mRNA and protein levels. In vivo experiments show that B-CM enhances the tumor inhibition effect of OXa, which is related to the reduction of the expression of Ki-67 and MDR1 in tumor tissues. Further, it can be shown that the soluble factor derived from Blautia can reverse the drug resistance of colorectal cancer to oxaliplatin by down-regulating MDR1 and inhibiting epithelial-mesenchymal transition. This shows that Blautia-derived metabolites are a promising new adjuvant strategy to overcome chemotherapy resistance of colorectal cancer.

This invention relates to the field of special medical foods, and particularly to a special medical food formula for colorectal cancer patients, its preparation method, and its application. The raw materials, in parts by weight, include: 20-30 parts Codonopsis pilosula, 20-30 parts Rehmannia glutinosa (processed), 20-30 parts Astragalus membranaceus, 10-20 parts Coix lacryma-jobi (raw), 10-20 parts Atractylodes macrocephala, 10-20 parts Poria cocos, 10-20 parts Angelica sinensis, 10-20 parts Paeonia lactiflora, 10-20 parts Prunus persica, 3-6 jujubes, 3-15 parts Glycyrrhiza uralensis, 6-15 parts phycocyanin, and 6-15 parts citric acid. This formula can have anti-tumor effects, reduce the toxic side effects of chemotherapy, enhance the reticuloendothelial cell system, promote the enhancement of specific and non-specific immune functions in the body, thereby reducing tumor volume and inhibiting tumor proliferation and metastasis. The drug is encapsulated in Dunaliella salina exosomes and targeted modified to ensure accurate delivery to the lesion site, increasing bioavailability and reducing the drawbacks of a small therapeutic window and high toxicity.

This invention discloses the application of fruquintinib combined with PD-1 monoclonal antibody in maintenance therapy for HER-2 negative advanced gastric cancer / geoesophageal junction adenocarcinoma, belonging to the field of tumor treatment technology. This invention targets HER2-negative advanced gastric cancer or gastroesophageal junction adenocarcinoma, specifically patients who achieve disease control after 3 months of first-line induction therapy with PD-1 monoclonal antibody combined with oxaliplatin, followed by maintenance therapy with fruquintinib combined with PD-1 monoclonal antibody without chemotherapy. The maintenance therapy regimen provided by this invention improves patients' quality of life and prolongs overall survival while delaying disease progression, and has significant clinical implications.

This invention belongs to the field of traditional Chinese medicine technology, and relates to a topical Chinese medicine composition, topical drug, topical patch, acupoint patch, and preparation method and application for treating nausea and vomiting caused by chemotherapy for intracranial tumors. The Chinese medicine composition consists of the following raw materials in parts by weight: 1-2 parts of Ligusticum chuanxiong, 1-2 parts of Gastrodia elata, 2-4 parts of Uncaria rhynchophylla, 1-2 parts of Citrus aurantium, 1-2 parts of Sinapis alba, 1-2 parts of Clematis chinensis, 0.5-1 part of Melia toosendan, 0.5-1 part of Panax ginseng, 1-2 parts of Pinellia ternata, 1-2 parts of Albizia julibrissin bark, 0.5-1 part of Lentinus edodes, and 1-2 parts of Astragalus membranaceus. This Chinese medicine composition has the effects of relieving nausea and vomiting, soothing the liver and strengthening the spleen, detoxifying and eliminating turbidity, calming the liver and extinguishing wind, and calming the mind and soothing the nerves. It not only effectively controls the nausea and vomiting symptoms caused by chemotherapy for intracranial tumors, but also harmonizes the body's Qi and organ functions. The Chinese medicine composition has a simple formula, widely available ingredients, and a simple preparation method; it is for topical application, convenient for clinical use, and has low adverse reactions.

The present invention is in the field of molecular subtyping of tumor samples and therapy guidance. The present invention relates to methods, arrays, prognostic assays, systems and uses thereof for prediction of the response or resistance to and / or benefit from a systemic treatment, in particular adjuvant or neoadjuvant chemotherapy, of a subject suffering from a HR+ and HER2− breast cancer, based on the measurement(s) of expression level(s) of three or more markers in tumor samples of said subject. Equally, the present invention relates to methods, arrays, prognostic assays, systems and uses thereof for prediction of the outcome benefit from a systemic treatment, in particular adjuvant or neoadjuvant chemotherapy, of a subject suffering from a HR+ and HER2− breast cancer, based on the measurement(s) of expression level(s) of three or more markers in tumor samples of said subject.

This invention discloses a multi-directional flow nozzle for intraperitoneal hyperthermic perfusion chemotherapy, belonging to the field of medical device technology. It includes a nozzle body, one end of which is connected to a drainage conduit for connecting to a chemotherapy pump. The nozzle body includes a nozzle head and a connecting tube. One end of the connecting tube is fixedly connected to the nozzle head, and the other end is connected to the drainage conduit. Multiple through holes are evenly distributed on the nozzle head. A rotor is rotatably mounted inside the connecting tube. The connecting tube includes a Venturi tube segment and a connecting section. The rotor is positioned within the throat of the Venturi tube segment. A variable-diameter channel is located at the center of the rotor, and multiple guide vanes are evenly distributed circumferentially along a fixed support rod at the center of the variable-diameter channel. Water flow causes the rotor to rotate, inducing a vortex field in the intraperitoneal medication through the guide vanes. This invention forms a dynamic circulation under pressure, significantly improving the uniformity of contact between the medication and the peritoneal wall, especially small peritoneal metastases. The reaction force of the water flow drives the nozzle head to rotate or form a vortex, greatly improving the therapeutic effect of intraperitoneal hyperthermic perfusion chemotherapy.

The application provides application of a hydrogen sulfide donor SPRC in improving early-onset ovarian dysfunction caused by a chemotherapy drug, and relates to the technical field of biomedicine, and the technical key points are as follows: the application provides application of the hydrogen sulfide donor SPRC in preparing a drug for improving early-onset ovarian dysfunction. The present application aims at the technical problems of early-onset ovarian dysfunction causing the decline of female ovarian function and reproductive capacity, including the decline of ovarian index, the reduction of the number of follicles at all levels, and the significant increase of the number of apoptotic cells in ovarian tissue. The specific verification experiments prove that supplementing the hydrogen sulfide donor SPRC in a mouse model of early-onset ovarian dysfunction can improve the body weight and ovarian index of the mouse, and maintain the normal morphology of the ovary. Specifically, the SPRC can improve the number and quality of follicles in the ovary by reducing cell apoptosis, and ultimately rescue the ovarian damage caused by POI.

The application relates to the field of health assessment, and particularly discloses a ZNF281-based gastric cancer prognosis value evaluation system, which comprises a ZNF281 expression quantification module, which is used for detecting the protein / RNA expression level of ZNF281 in tumor tissue through immunohistochemistry, real-time fluorescent quantitative PCR or Western blot technology; a stemness feature and signal path analysis module, which is used for acquiring the protein expression or cell positive rate of stemness genes CD44 and SOX9; then evaluating the activation state of an IL6 / JAK / STAT3 path, including Western blot detection of a p-STAT3 / STAT3 ratio, ELISA determination of IL6 and CXCL5 cytokine levels; then analyzing the cancer-associated fibroblast infiltration in a tumor microenvironment, quantifying the CAF density through alpha-SMA immunofluorescence staining, and combining single-cell sequencing analysis of the interaction strength of a CXCL5 / CXCR2 signal shaft. The technical scheme of the application can integrate the expression amount of ZNF281, signal path activity and clinical pathological data, and precisely stratify the chemotherapy sensitivity and prognosis of gastric cancer patients.

The present application belongs to the technical field of medical apparatus and instruments, in particular to a tumor nursing dispensing device and its using method, aiming at solving the problem of liquid back-spraying and poor dissolving effect of the existing dispensing method, the device comprises a base, a bearing tray, a lifting arm and an injection mechanism, the injection mechanism comprises a sliding groove and a pressing plate, the outer wall of the piston cylinder is provided with a back-spraying prevention mechanism, which comprises a fixing ring and an outer sleeve, when the needle is pierced, the positive pressure generated in the bottle is introduced into the air bag to absorb the pressure and prevent the liquid from back-spraying when the needle is pulled out, a shaking mechanism is arranged between the base and the bearing tray, comprising a metal ring, a vertical rod and a supporting mechanism, the mechanism can make the bearing tray produce a conical swing trajectory similar to nutation while driving the bearing tray to rotate, forming liquid vortex in the medicine bottle to gently dissolve the freeze-dried powder of chemotherapy, avoiding the generation of harmful bubbles, the device can effectively reduce the risk of liquid back-spraying and improve the uniformity of drug dissolution and the accuracy of dosage.

The application provides an embolism microsphere for regulating a tumor microenvironment and a preparation method and application thereof. The prepared embolism microsphere for regulating the tumor microenvironment is used for arterial tumor embolism, can embolize tumor blood vessels, block nutrition supply at a tumor site, and slowly and continuously release hydroxide in situ, neutralize lactic acid in the tumor microenvironment, regulate the weakly acidic tumor microenvironment, and improve the effect of chemotherapy, radiotherapy and immunotherapy.

The application provides use of an inhibitor targeting IL-11 or an IL-11 receptor in preparation of a drug for delaying ovarian aging, and first discloses and proves that an inflammatory factor interleukin-11 (IL-11) is a core target point for driving ovarian aging and an increase in ovarian matrix stiffness and fibrosis under pathological conditions such as chemotherapy damage and polycystic ovary syndrome, and the interleukin-11 promotes excessive secretion of collagen by activating an IL-11RA / ERK signal axis in ovarian fibroblasts. Based on this, the application provides a new use of an inhibitor (such as specific siRNA and a neutralizing antibody) targeting IL-11 or the receptor thereof in preparation of a related therapeutic drug. In particular, a liposome nanoparticle loaded with IL-11 siRNA can effectively reduce ovarian stiffness, reduce fibrosis, significantly improve follicle reserve, hormone level and fertility, and successfully reverse the ovarian aging phenotype in old mice, rats and various disease models. The application provides a new effective target point, a treatment strategy and a product prototype with a transformation potential for intervention on ovarian aging and related diseases.

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

The present disclosure provides methods for treating or inhibiting the growth of lung cancer in a subject in need thereof, comprising administering a LAG-3 inhibitor (e.g., an anti-LAG-3 antibody or antigen-binding fragment thereof) in combination with a PD-1 inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof). In certain embodiments, the administration of the PD-1 inhibitor enhances the efficacy of the LAG-3 inhibitor in inhibiting the growth of lung cancer. In certain embodiments, the administration of the PD-1 inhibitor and the LAG-3 inhibitor in combination with a platinum doublet chemotherapy enhances efficacy in treating lung cancer. In certain embodiments, following the administration of the PD-1 inhibitor and the LAG-3 inhibitor in combination with a platinum doublet chemotherapy, surgery to resect the cancer and adjuvant therapy, including further administration of the PD-1 inhibitor and the LAG-3 inhibitor, can be performed.

The application discloses a bladder cancer chemotherapy auxiliary device, which comprises a connecting box, suction cups are fixedly connected to the four corners of the bottom side outer wall of the connecting box, a drainage hose is communicated and arranged at the middle shaft of the side wall of the connecting box, a liquid spraying head is communicated and arranged at the end of the drainage hose away from the connecting box, a pressurizing pipe is arranged at the middle shaft of the top of the connecting box, a liquid inlet pipe is communicated and arranged at the upper side wall of the pressurizing pipe, and a pipe cap is screw-connected to the outer side wall of the end of the liquid inlet pipe away from the pressurizing pipe. When it is necessary to add medicine to a patient, a staff member can add liquid medicine into the pressurizing pipe through the liquid inlet pipe, and then the liquid medicine can enter the inside of the connecting box; then the staff member presses down the push disc and the push rod, the downward movement of the push rod drives the downward movement of the pressurizing disc, and under the effect of pressure, the liquid medicine can be sprayed on the diseased part of the patient through the drainage hose and the liquid spraying head, thereby achieving the purpose of adding medicine.

Method for treating cancer in a patient consisting of administering a systemic chemotherapy regimen in combination with radioactively labeled particles, characterized in that both therapies, when introduced into the patient, have an enhanced anticancer effect.

A Pt(Ⅳ) complex is provided, which, as a prodrug, is activated by irradiation to release a Pt(II) complex for treating tumors. A pharmaceutical composition comprising said Pt(Ⅳ) complex is also provided, as well as the use of said Pt(Ⅳ) complex in the preparation of a medicament for irradiation-activated treatment of tumors. A kit comprising said Pt(Ⅳ) complex and instructions for use, the instructions indicating that radiotherapy should be administered after administration to treat tumors, is also provided.

The present invention relates to a method of predicting a response to lung cancer immunotherapy of a patient suffering from lung cancer. Further, the present invention relates to a method of providing a survival prognosis to a patient suffering from lung cancer who is eligible to immunotherapy. Furthermore, the present invention relates to a method of determining whether to treat a patient suffering from lung cancer with immunotherapy. In addition, the present invention relates to a method of selecting a patient suffering from lung cancer to benefit from immunochemotherapy or immunotherapy. Moreover, the present invention relates to a kit for carrying out these methods.